An exciting finding in the field of cancer immunotherapy has been the identification of immune checkpoints, particularly CTLA-4 and PD-1/PD-L1, which serve as key regulators in protecting tumors from immune attacks (Qin et al., 2019[79]). Here, PDCD1 is linked to cancer.